Prazosin
- Generic Name
- Prazosin
- Brand Names
- Minipress, Minizide
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21N5O4
- CAS Number
- 19216-56-9
- Unique Ingredient Identifier
- XM03YJ541D
- Background
Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.
Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.
- Indication
This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents .
Prazosin does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (COPD).
- Associated Conditions
- Agitation, Benign Prostatic Hyperplasia (BPH), Hypertension, Raynaud's Phenomenon, Disturbed sleep/nightmares
- Associated Therapies
- -
The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study
- Conditions
- Cigarette Smoking ToxicityNicotineAcute Cardiovascular Disease
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- University of Louisville
- Registration Number
- NCT03010995
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 70
- Registration Number
- NCT02966340
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Prazosin for Post-Concussive Headaches
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2024-07-10
- Target Recruit Count
- 89
- Registration Number
- NCT02965027
- Locations
- 🇺🇸
Madigan Army Medical Center, Tacoma, Washington, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity
- Conditions
- DepressionPosttraumatic Stress DisorderMild Cognitive ImpairmentAlcohol-Related DisordersSubstance-Related DisordersWounds and InjurySuicidal IdeationBrain InjuriesQuality of LifeChronic Disease
- Interventions
- Behavioral: Motivational InterviewingBehavioral: Cognitive Behavioral Therapy ElementsBehavioral: Care ManagementDrug: FluoxetineDrug: FluvoxamineDrug: ParoxetineDrug: SertralineDrug: CitalopramDrug: VenlafaxineDrug: DuloxetineDrug: MirtazapineDrug: DiphenhydramineDrug: TrazodoneDrug: Prazosin
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 635
- Registration Number
- NCT02655354
- Locations
- 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Honor Health, Scottsdale, Arizona, United States
Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress
- Conditions
- HypertensionStress, PsychologicalBlood Pressure
- Interventions
- Drug: PlaceboDrug: Prazosin
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 50
- Registration Number
- NCT02431936
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD
- Conditions
- Bulimia NervosaStress Disorders, Post-Traumatic
- Interventions
- Drug: PrazosinDrug: Placebo
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02382848
- Locations
- 🇺🇸
Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders
- Conditions
- Alcohol Use DisorderPosttraumatic Stress Disorder (PTSD)
- Interventions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2020-12-29
- Target Recruit Count
- 31
- Registration Number
- NCT02322047
- Locations
- 🇺🇸
VA Puget Sound Healthcare System, Seattle, Washington, United States
Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)
- Conditions
- NightmaresSuicidal IdeationPost Traumatic Stress Disorder
- Interventions
- Drug: PlaceboDrug: Prazosin
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 20
- Registration Number
- NCT02199652
- Locations
- 🇺🇸
Georgia Regents University, Augusta, Georgia, United States
Varenicline + Prazosin for Heavy Drinking Smokers
- Conditions
- Alcohol Use DisordersCigarette Smoking
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Yale University
- Target Recruit Count
- 5
- Registration Number
- NCT02193256
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 36
- Registration Number
- NCT01916941
- Locations
- 🇺🇸
University of New Mexico, Department of Psychiatry, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.